SCHEMBL8915442

SCHEMBL8915442

CCOC(=O)NC(C)C(=O)CC

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
GAA P10253 2/20 0.39
MGAM O43451 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
SOAT1 P35610 1/20 0.39
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 2/20 0.37
ATM Q13315 1/20 0.36
HSD17B10 Q99714 1/20 0.36
ACACB O00763 1/20 0.35
ALOX15 P16050 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
METAP2 P50579 2/20 0.34
METAP1 P53582 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19578417 1.00 SMN1; SMN2 (0.41) SMN1; SMN2LMNAHTTGAAMGAM
SCHEMBL19334094 1.00 SMN1; SMN2 (0.41) SMN1; SMN2LMNAHTTGAAMGAM
SCHEMBL22751568 0.83 METAP2 (0.46) SMN1; SMN2LMNAHTTGAAMGAM
SCHEMBL11189746 0.83 METAP2 (0.46) SMN1; SMN2LMNAHTTGAAMGAM
SCHEMBL14816710 0.83 ACACB (0.35) SMN1; SMN2GAAACACBCYP2C9
SCHEMBL8915661 0.83 ACACB (0.35) SMN1; SMN2GAAACACBCYP2C9
SCHEMBL8917694 0.83 ACACB (0.35) SMN1; SMN2GAAACACBCYP2C9
SCHEMBL24950429 0.81 TSHR (0.49) SMN1; SMN2LMNAHTTGAAMGAM
SCHEMBL3551870 0.81 TYR (0.44) SMN1; SMN2LMNAHTTGAAMGAM
SCHEMBL753926 0.81 TYR (0.44) SMN1; SMN2LMNAHTTGAAMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188132-B2 Linked dibenzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
US-20100226883-A1 LINKED DIIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-09 US disclosed
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226883-A1 LINKED DIIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 SMN1; SMN2 3298/4885LMNA 2096/4885HTT 4357/4885
US-20100221214-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES EIF2AK2, NSUN2, ZC3HAV1 SMN1; SMN2 3515/4885LMNA 2724/4885HTT 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.